抗うつ薬の効果とうつ病の重症度:患者レベルのメタ解析
Jay C Fournier1, Robert J DeRubeis, Steven D Hollon
1Department of Psychology, University of Pennsylvania, 3720 Walnut St, Philadelphia, PA 19104, USA. jcf@sas.upenn.edu
JAMA
|January 7, 2010
まとめ
抗うつ薬の効用は,うつ病の重度によって異なります. 軽度から中等度のうつ病では,薬はプラセボよりもわずかな利点を提供します. しかし,重度のうつ病では,抗うつ剤はプラセボと比較して実質的な利点を示しています.
科学分野:
- 臨床心理学の臨床心理学について
- 精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは,精神薬理学 (Psychopharmacology) とは
- 医学研究 医学研究
背景:
- 抗うつ薬は,メジャーうつ病の主要な治療法である.
- 軽度のうつ病におけるプラセボよりも特定の薬理学的効果の証拠は限られている.
- 症状の重度を超えて治療の有効性を理解することは,臨床実務において極めて重要です.
研究 の 目的:
- 抗うつ薬の比較効果とプラセボの比較効果を定量化するために.
- この相対的な利益が初期うつ病症状の重症度によってどのように変化するかを評価する.
- 重度のうつ病の治療ガイドラインを参考にするために.
主な方法:
- PubMed,PsycINFO,およびコクラン図書館 (1980-2009) の体系的な文献検索を行いました.
- FDAが承認した抗うつ剤のランダム化プラセボ対照試験 (RCT) を含む.
- ハミルトンうつ病評価スケール (HDRS) を使用した6つのRCT (718人の患者) の個々の患者レベルのデータの分析.
主要な成果:
- 薬剤とプラセボとの差異は,うつ病の発症の重さに強く依存していました.
- HDRSスコアが23未満の患者では,効果の大きさは小さい (Cohen d < 0.20) でした.
- 臨床的有意性は,HDRSスコアが25以上で観察され,より重症な症例ではより大きな薬剤効果を示しています.
結論:
- プラセボよりも抗うつ薬の治療的効果は,うつ病の重度とともに増加します.
- 軽度から中等度のうつ病の場合,薬の利点は最小限か全くない場合があります.
- 抗うつ薬は重度のうつ病を患っている患者に大きな利点をもたらします.
関連する概念動画
Antidepressant Drugs: MAOIs and Other Agents
1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
2.0K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.0K
Antidepressant Drugs: Overview
1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Depression: Overview
1.1K
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.1K
Depressive Disorders: Etiology
832
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
832
Depressive Disorders: MDD and Dysthymia
1.0K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.0K


